arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Crinetics Pharmaceuticals, Inc.

CRNX

$84.96 0.00 (0.00%) at close

11 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Crinetics Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.0B

Dividend Yield —

Revenue Growth 640.7% ↗

Op. Margin None

ROIC -41.2% ↘

FCF / Share $-4.08 ↘

Trailing P/E —

Price / Book 8.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 31, 2026.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$7.70M

↑ +640.7% —

Net Income Profit after all expenses

$-465.32M

↓ -55.9% —

FCF / Share Free cash flow per share

$-4.08

↓ -43.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue Growth YoY (%)	640.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+7909%)	-74.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1026%)	-15.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-291%)	339.4% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4143%)	1418.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+17629%)	-94.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1276%)	-50.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-736%)	18.7% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+134%)	247.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2990%)	—	—
EPS Growth YoY (%)	-34.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-17.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-12.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-55.9% Weak ↓ Weak Declining Year-over-year change in net income	-39.1% Weak ↑ Weak Improving Year-over-year change in net income	-30.9% Weak ↑ Weak Improving Year-over-year change in net income	-52.3% Weak ↑ Weak Improving Year-over-year change in net income	-45.8% Weak ↑ Weak Improving Year-over-year change in net income	-46.4% Weak ↑ Weak Improving Year-over-year change in net income	-86.0% Weak ↑ Weak Improving Year-over-year change in net income	-196.1% Weak Weak Year-over-year change in net income	-52.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-43.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	3.4% Caution ↑ Caution Improving Year-over-year change in free cash flow	-31.0% Weak Weak Year-over-year change in free cash flow	2.9% Caution Caution Year-over-year change in free cash flow	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	17.6% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	-1.2% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	283.8% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	58.4% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-23.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-67.4% Weak Weak Compound annual revenue growth over 3 years	26.5% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	155.3% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	-2.7% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	10.6% Good ↓ Good Declining Compound annual revenue growth over 5 years	18.3% Excellent Excellent Compound annual revenue growth over 5 years	12.8% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	-446.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3075%)	—	—
Effective Tax Rate (%) (%)	—	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	-447.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3831%)	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	—	-478.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Return on Invested Capital (%)	-41.2% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-25.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.3% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-53.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-44.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	60.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	97.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-45.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-35.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-40.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-58.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-46.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-413%)	-22.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-250%)	-39.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-365%)	-51.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-445%)	-32.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-316%)	-43.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-391%)	-43.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-387%)	-16.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-213%)	61.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+306%)	97.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+547%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	—	-1140.88x Weak Weak Operating income divided by interest expense Optimal: > 5x	-549.45x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-101.54M	$-264.55M	$-54.90M	$-32.67M	$-200.69M	$-93.09M	$-40.33M	$-44.97M	$-14.19M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue per Share (USD)	$0.08	$0.01	$0.07	$0.09	$0.03	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-4.95	$-3.69	$-3.69	$-3.15	$-2.80	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-4.08	$-2.84	$-2.94	$-2.25	$-2.32	—	—	—	—	—	—
Book Value per Share (USD)	$10.38	$14.26	$7.91	$5.87	$6.97	$5.12	$4.83	—	$-9.69	—	—
Tangible Book Value per Share (USD)	$10.38	$14.26	$7.91	$5.87	$6.97	$5.12	$4.83	—	$-9.69	—	—
Basic Weighted Avg Shares (shares)	94.06M	80.78M	58.07M	51.98M	38.44M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Working Capital (USD)	$963.27M	$1.32B	$530.21M	$317.46M	$328.73M	$167.00M	$115.00M	$158.76M	$14.27M	—	—
Total Equity (USD)	$992.08M	$1.32B	$539.11M	$316.33M	$331.94M	$168.92M	$117.14M	$160.22M	$-15.02M	$-6.20M	$-463.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Sales/Revenue/Turnover (USD)	$7.70M	$1.04M	$4.01M	$4.74M	$1.08M	$71.00K	$1.19M	$2.43M	$2.04M	$589.00K	—
Depreciation Expense (USD)	$3.90M	$2.80M	$1.10M	$1.00M	$900.00K	$900.00K	$900.00K	—	—	—	—
Net Income, GAAP (USD)	$-465.32M	$-298.41M	$-214.53M	$-163.92M	$-107.64M	$-73.81M	$-50.42M	$-27.11M	$-9.16M	$-6.02M	—
Operating Cash Flow (USD)	$-377.92M	$-225.97M	$-166.31M	$-115.20M	$-88.59M	$-62.03M	$-46.38M	$-19.46M	$-9.48M	$-5.47M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 39 quarters

Crinetics Pharmaceuticals, Inc.

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CRNX with peers